In parallel, we administered fat-6 RNAi to WT, glp-1(-), fem-3(-) , and mog-3(-) worms to verify the effectiveness of the RNAi treatment on fat-6
Limitations of Current Research Many studies are preclinical Human mechanistic trials remain limited Microbiome responses vary individually Diet, sleep, stress, and medications influence outcomes GLP-1 regulation is multi-factorial The microbiome is one variable within a complex endocrine network
The JPML decided to add Saxenda but did not add the new injuries to the existing MDL
Fertility and Sterility, 121 (2), 215222.
Article 2 mins Rebuilding for Resilience: Lessons Learned from Hurricane Ian In the wake of Hurricane Ian, Aon sent a team of experts to the affected area to understand the lessons learned from this storm
According to Fortune Business Insights, the oncology drug market was valued at around $220 billion in 2024 and is projected to hit $518 billion by 2032